Vertex Pharmaceuticals Inc (VRTX) stock
VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3028% above fair value
$547.03−0.86 (-0.16%)
Close on Nov 11, 2026Market cap $138.65BP/E 31.8Yield –
Vertex Pharmaceuticals EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Vertex Pharmaceuticals's EV/EBITDA was 26.2× on Nov 11, 2026, against 24.8× a year earlier. Over the last 5 years it ranged from 14.3× to 27.3×, with a median of 20.0×.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 26.2× | +0.2 |
| 2025 | Dec 31, 2025 | 26.0× | −0.9 |
| 2024 | Jul 31, 2024 | 26.9× | +3.8 |
| 2023 | Dec 29, 2023 | 23.0× | +8.0 |
| 2022 | Dec 30, 2022 | 15.0× | −2.8 |
| 2021 | Dec 31, 2021 | 17.8× | −2.2 |
| 2020 | Dec 31, 2020 | 20.0× | −39.9 |
| 2019 | Dec 31, 2019 | 59.9× | +4.0 |
| 2018 | Dec 31, 2018 | 55.9× | −318.1 |
| 2017 | Dec 29, 2017 | 374.1× | +180.9 |
| 2013 | Apr 30, 2013 | 193.1× | +167.1 |
| 2012 | Dec 31, 2012 | 26.0× | – |
See a number that looks wrong?